Alterra Prestent + SAPIEN 3 Valve for Heart Disease
Trial Summary
Do I need to stop my current medications for the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, if you have an active infection requiring antibiotics, you must wait two weeks after stopping them to be eligible.
Is the Alterra Prestent + SAPIEN 3 Valve generally safe for humans?
The Alterra Prestent and SAPIEN 3 Valve have been studied for safety in patients with heart valve issues, showing promising results. The SAPIEN 3 Valve has been used in high-risk patients and was found to be as safe as traditional surgery, with improvements to reduce risks like vascular injury and leakage.12345
How is the Alterra Prestent + SAPIEN 3 Valve treatment unique for heart disease?
The Alterra Prestent + SAPIEN 3 Valve treatment is unique because it combines a specialized prestent with a transcatheter heart valve, offering a minimally invasive option for heart valve replacement, which can be particularly beneficial for patients who are not candidates for traditional open-heart surgery.678910
What is the purpose of this trial?
To demonstrate the safety and effectiveness of the Edwards Alterra Adaptive Prestent in conjunction with the Edwards SAPIEN 3 Transcatheter Heart Valve (THV) System in subjects with a dysfunctional right ventricular outflow tract/pulmonary valve (RVOT/PV) who are indicated for treatment of pulmonary regurgitation (PR).Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.
Research Team
Evan Zahn, MD, FACC, FSCAI
Principal Investigator
Cedars-Sinai Heart Institute
Eligibility Criteria
This trial is for individuals weighing at least 44 lbs with certain heart conditions like Tetralogy of Fallot, who have moderate or severe pulmonary regurgitation. They must have specific measurements in their heart's outflow tract and agree to the study terms. People can't join if they've had recent medical procedures, drug abuse history, are pregnant, have serious non-cardiac diseases, infections requiring antibiotics, blood disorders or known allergies to specific metals and medications.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Implantation of Edwards Alterra Adaptive Prestent and Edwards SAPIEN 3 THV using either Commander or Pulmonic Delivery System
Follow-up
Participants are monitored for safety and effectiveness after treatment
Continued Access
Subjects are eligible for enrollment in the continued access phase of the trial
Treatment Details
Interventions
- Edwards Alterra Adaptive Prestent
- Edwards SAPIEN 3 THV
Find a Clinic Near You
Who Is Running the Clinical Trial?
Edwards Lifesciences
Lead Sponsor
Todd Brinton
Edwards Lifesciences
Chief Medical Officer since 2023
MD from Stanford University
Bernard Zovighian
Edwards Lifesciences
Chief Executive Officer since 2023
MBA from INSEAD